Method of treating corneal ulcers

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly ophthalmology, and may be used for treating corneal ulcer. That is ensured by the integrated treatment including the intake of Lymphomyosot 10 drops in 50-100 ml of water three times a day for three weeks; Traumel 1 tablet 3 times daily for three weeks sublingually; 10 subcutaneous 2.2 ml injections twice a week: Mucosa Compositum, Solidago Compositum, Coenzyme Compositum; 10 subcutaneous 2.2 ml injections of Traumeel every second day; eye instillations of Oculoheel, okulohelya, Mydriacyl and colloidal silver 2 drops 3 times a day for 10 days; sea buckthorn oil under the eyelid 3 times a day for 10 days; Solcoseryl ointment or gel in the conjunctival cavity until observing the complete epithelialisation, and also the radiotherapy course from the first day of treatment in a dose of 50 cGy daily, within 5 sessions. The severe corneal opacities require the additional 5 sessions of the repeated radiotherapy course in a dose of 500 cGy daily following the 5-session radiotherapy course in a dose of 50 cGy three months later.

EFFECT: method enables increasing or recovering the visual acuity ensured by ulcer epithelisation with no side effects.

2 ex

 

The invention relates to medicine, in particular to ophthalmology.

Corneal ulcer is a serious disease that is difficult to treat and usually ends with a different degree of intensity of visual impairment, including blindness;.

Diseases of the cornea constitute 20-25% of ocular pathology.

Ulcerative lesions are divided into infectious and non-infectious. The development of infectious ulcerative lesions depends on many factors, complications during and after surgery removal of pterygium, surgeries eyelids, lacrimal tubules inflammation of the conjunctiva, long instillation of antibiotics, anesthetics, corticosteroids.

The main clinical factors of corneal ulcers are bacteria, herpes virus infection, fungal, parasitic, regional allergic reaction, primary corneal dystrophy.

The disease begins abruptly: there photophobia, tearing, pain, eye pain, foreign body sensation, conjunctival chemosis. In the process involves the iris and ciliary body, iridocyclitis occurs.

The closest analogue is a method of treatment involving the use of broad-spectrum antibiotics topically as drops, injections of steam and retrobulbarno, ointments, non-steroidal, anti-viral drugs ("Selected lectures on ophthalm the biology / edited by takhchidi HP, Moscow, 2007, volume 1, str-224).

However, this method has significant disadvantages of each of these drugs can cause unwanted side effects: acute, allergic reactions, suppression of the adrenal cortex, in long-term care develops syndrome Yatsenko-Cushing syndrome, may increase blood and intraocular pressure. Also the above therapy is contraindicated in patients with diabetes, pregnant and lactating women, epilepsy, nephropathy and ischemic heart disease.

The objective of the invention is the creation of effective treatment of ulcers of the cornea.

The technical result of the invention is epithelialization of ulcers and increase or restore visual acuity.

The technical result is achieved in that in the method of treating ulcers of the cornea by the use of medicines, according to the invention, carry out comprehensive treatment, including ingestion of Lymphomyosot 10 drops in 50-100 ml of water 3 times a day for three weeks, traumas sublingual 1 tablet 3 times a day for three weeks; injection under the skin twice a week, a total of 10 injections of 2.2 ml: mucosa compositum, Solidago compositum, coenzyme compositum; injection under the skin of traumas 2.2 ml every other day, just 10 injections; instillation in the eye for 10 days to 2 ka is whether 3 times a day oculoheel, mydriacyl and colloidal silver; sea buckthorn oil for cat 3 times a day for 10 days; ointment or jelly solkoseril in the conjunctival cavity until complete epithelialization, and radiation therapy from the first day of treatment at 50 cGy daily, just 5 sessions.

At a rough corneal opacities, three months after the end of radiotherapy course of 5 sessions of 50 cGy, advanced refresher course radiation therapy 500 cGy daily, just 5 sessions.

According to the invention the introduction of antihomotoxic preparations in these dosages, namely Lymphomyosot, traumas, mucosa compositum, Solidago compositum, coenzyme compositum; allows you to quickly remove toxins, eliminate pain in the eye, to restore the immune system that promotes the healing of ulcers of the cornea.

Lymphomyosot provides lymphatic drainage, protivoekssudativnoe, detoxification, anti-allergic effect. The Traumeel anti-inflammatory, antiexudative, immune-stimulating, regenerating, analgesic, Antihemorrhagics, wendonside action. Mucosa compositum is a drug with pronounced immunostimulating, reparative, anti-inflammatory, Antihemorrhagics properties.

Solidago compositum harmonizes the work of the kidneys.

Coenzyme compositum activates tissue on the Chania oxidation - regenerative processes (Krebs cycle), have antioxidant and detoxifying action.

Oculoheel local anti-inflammatory, reparative action.

Mydriacyl dilates the pupil, thus, prevents the formation of posterior synechia.

Colloidal silver is a natural antibiotic that is non-toxic to the human body, is effective against many species of bacteria. Sea buckthorn oil and alkoxysilane butter or jelly help to accelerate the process of regeneration.

Rays in a daily dose of 50 cGy-inflammatory effect, under which reduced the time of emigration of leukocytes, strengthens the processes of regeneration of the epithelium. At a rough corneal opacities, three months after the end of the first course of radiation therapy, advanced refresher course radiation therapy 500 cGy daily, just 5 sessions. Rays in a daily dose of 500 cGy impede the growth of newly formed blood vessels and increase the transparency of the cornea.

Example 1

In MNTK "eye microsurgery" asked the patient K. 43 years with complaints about the blindness of the right eye and the right svetoproekt left eye, the pain in my left eye, watery eyes. History of diabetes mellitus (insulin dependent) and type 2. Right eye operated on for tractional retinal detachment. Sharp is one of the right eye - 0.

Left eye - right svetoproekt. Swelling of the eyelids, conjunctiva injected, corneal edema, in the centre of the ulcer, rounded with saped edges, occupying 2/3 of the area of the cornea. Ulcer occurred 2 months after vitrectomy: hemophthalmus on the background of diabetic retinopathy, suspicion on the valve gap.

After surgery the patient within 2 months was prescribed the Dexamethasone, Tobradex, Intecolor, Arutema, Azopt, which resulted in corneal ulcers and the risk of vision loss.

On Reckeweg ulcer of any localization refers to the 5 phase genotoxicity: this cell phase, in which the increasing destruction of cellular systems and security forces are not able to remove toxins from the matrix (regulation stupor), this phase includes diabetes.

With the phase of homotoxins the patient had received treatment according to the invention, namely: the ingestion of Lymphomyosot 10 drops per 50 ml of water 3 times a day for three weeks, traumas sublingual 1 tablet 3 times a day for three weeks, injections under the skin twice a week, a total of 10 injections of 2.2 ml: mucosa compositum, Solidago compositum, coenzyme compositum; injection under the skin of traumas 2.2 ml every other day, just 10 injections; instillation in the left eye for 10 days to 2 drops 3 times a day: oculoheel, mydriacyl and colloidal silver; oil is sea buckthorn for eyelid of the left eye 3 times a day for 10 days; the ointment solcoseryl in the conjunctival cavity of the left eye 10 days, and conducted a course of radiation therapy on the first day of treatment the ulcer 50 cGy daily, just 5 sessions.

Two weeks later, visual acuity of the left eye improved to 0.01, showed signs of epithelialization of corneal ulcers.

In the treatment of corneal ulcer healed, the cornea is enlightened, the visual acuity improved to 0.5 and remains high until the present time. The patient took off the blind. In addition to the positive ophthalmic result of her improved blood sugar and quality of life.

The observation period of 3 years.

Example 2

In MNTK "eye microsurgery" was directed patient B., 49, with recurrent ulcer of the cornea.

During the year there was a six exacerbations of the disease, the standard treatment was given an unstable effect and remission was short-lived, up to 1.5-2 weeks.

When handling visual acuity of the left eye the right projection light, visual acuity of the right eye and 1.0.

Marked swelling of the eyelids, lacrimation, photophobia, injected conjunctiva, the cornea in the center of the ulcer, which occupies ¾ of the area of the cornea. With the phase of genotoxicity and gross clouding of the cornea, the patient had received treatment according to the invention, namely: the ingestion of Lymphomyosot 10 drops per 100 ml of water 3 the Aza a day for three weeks, traumas sublingual 1 tablet 3 times a day for three weeks, injections under the skin twice a week, a total of 10 injections of 2.2 ml: mucosa compositum, Solidago compositum, coenzyme compositum; injection under the skin of traumas 2.2 ml every other day, just 10 injections; instillation in the left eye for 10 days to 2 drops 3 times a day: oculoheel, mydriacyl and colloidal silver; sea buckthorn oil for eyelid of the left eye 3 times a day for 10 days; jelly solkoseril in the conjunctival cavity of the left eye for two weeks and radiation therapy from the first day of treatment the ulcer 50 cGy daily, just 5 sessions. Three months after the end of the first course of radiation therapy is additionally conducted a second course of radiation therapy on ulcer 500 cGy daily, just 5 sessions.

In the treatment of corneal ulcer healed, the cornea is enlightened, the visual acuity improved to 0.2 and remained high up to the present time.

1. A method of treating ulcers of the cornea by the use of medicines, characterized in that conduct a comprehensive treatment, including ingestion of Lymphomyosot 10 drops in 50-100 ml of water 3 times a day for three weeks, traumas sublingual 1 tablet 3 times a day for three weeks; injection under the skin twice a week, a total of 10 injections of 2.2 ml: mucosa compositum, salt is ago compositum, coenzyme compositum; injection under the skin of traumas 2.2 ml every other day, just 10 injections; instillation in the eye for 10 days to 2 drops 3 times a day oculoheel, mydriacyl and colloidal silver; sea buckthorn oil for cat 3 times a day for 10 days; ointment or jelly solkoseril in the conjunctival cavity until complete epithelialization, and radiation therapy from the first day of treatment at 50 cGy daily, just 5 sessions.

2. The method according to claim 1, characterized in that at rough corneal opacities, three months after the end of the first course of radiation therapy, advanced refresher course radiation therapy 500 cGy daily, just 5 sessions.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be used for treatment of optic nerve atrophy of different etiology. Tree-component complex is implanted to patient in such a way that it covers optic nerve, posterior short ciliary arteries and part of retrobulbar cellular tissue, without joining them. Three-component complex contains mesenchymal stem cells, labeled with magnetic microparticles. Cells are transposed into biological or synthetic fine-porous material, which is tightly connected with polymer magnetic material with induction of constant magnetic field 1.5 mT, with multi-polar reversible magnetisation.

EFFECT: invention ensures improvement or stable stabilisation of visual functions, extension of vision field boundaries, acceleration of hemodynamics in retina and optic nerve.

2 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be used for surgical treatment of progressing and complicated myopia. As scleroplastic material implanted is three-component complex, which contains mesenchymal stem cells, labeled with magnetic microparticles. Cells are translocated into biological or synthetic fine-porous material, which is tightly connected with polymer magnetic material with induction of constant magnetic field 1.5 mT, with multi-polar reversible magnetisation.

EFFECT: invention ensures enhancement of strength-elastic properties of sclera, stabilisation of myopic process with simultaneous prevention of development of dystrophic changes of eye fundus or further progressing in case of their presence.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and deals with treatment of acute optic neuritis. Method includes introduction of traumeel sublingually in dose 1 pill three times per day, lymphomyosot in dose 10 drops in 50-100 ml of water three times per day for 3 weeks. Also made are 10 injection cpurses of the following medications: traumeel in dose 2.2 ml every second day, cerebrum compositum in dose 2.2 ml two times per week with 3 day interval, coenzyme compositum in dose 2.2 ml two times per week with 3 day interval, hepar compositum in dose 2.2 ml two days per week with 3 day interval. Method includes carrying out hirudotherapy by application of 2-3 leeches on the region of temple and behind ears two times per week for two weeks.

EFFECT: method ensures recovery of vision acuity, elimination of absolute and relative scotomas, recovery of colour perception, normal picture of eye fundus, as well as elimination of all signs of inflammation, elimination of pain during movement of eye balls, improvement of health state.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: device refers to new styrene derivatives with the structure formula A in the form of geometrical isomers or tautomers and their pharmaceutical acceptable salts. In structural formula (A) R1 represents hydrogen; R2 represents hydrogen or C1-C6alkyl; R3, R4, R5 and R6 are identical or different and independently represent hydrogen, halogen, C1-C6alkyl or -OR12; R7 represents hydrogen or C1-C6alkyl; R8 represents hydrogen; R9 represents hydrogen, C1-C6alkyl, or -C(=O)R13; R10 represents hydrogen or C1-C6alkyl; Z represents W-Y, wherein W represents -C(R14)(R15)-; Y represents -C(R16)(R17)-; each R12 independently represents hydrogen or C1-C6alkyl; each R13 independently represents C1-C6alkyl; R14 and R15 are identical or different, and independently specified in hydrogen, fluoro, methyl, ethyl, trifluoromethyl, -OH, -OCH3 or -NH2; or R14 and R15 together form oxo; R16 and R17 are identical or different and independently represent hydrogen, halogen, C1-C6alkyl or -OR12. The other radical values are specified in the patent claim.

EFFECT: compounds may be used for treating an ophthalmic disease or disorder in an individual which can represent age-related macular degeneration or Stargardt macular degeneration.

17 cl, 14 tbl, 143 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine, particularly to ophthalmology. An ophthalmic composition for treating keratoconjunctival damages and inflammations consists of an aqueous solution containing arabinogalactan 1 to 10 wt %, one or more preserving agents specified in a group consisting of sodium merthiolate, thimerosal, phenylmercuric nitrate or phenylmercuric acetate, phenylethyl alcohol, methyl-, ethyl-, propyl parabene, chlorhexidine acetate or gluconate or chlorobutanol, and containing no benzalkonium chloride. The ophthalmic composition is applied as a lacrimal substitute recommended for people wearing contact lenses.

EFFECT: group of inventions provides treating corneal erosions caused by wearing contact lenses.

16 cl, 5 tbl, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine, namely to ophthalmology, and can be applied for treatment of different diseases of eyes. Eye drops contain methylene blue, diphenhydramine hydrochloride, naphazoline hydrochloride, hydroxypropylmethylcellulose, boric acid, polyvinylpyrrolidone and distilled water in defined ratio of components.

EFFECT: invention ensures non-toxic and non-irritating anti-inflammatory, anti-infectious, anti-allergic action.

4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and is intended for treatment of refractive amblyopia in patients with high degree of myopia. Method includes surgical treatment excimer laser refractive operation Epi-LASIK. After operation, in case of complete epithelialisation, intravenous injections of ceraxon in dose 500 mg are made. Electrostimulation of retina and optic nerve are carried out simultaneously. Treatment is performed daily for 10 days.

EFFECT: method ensures high functional result and reduction of terms of visual rehabilitation in such patients, partially due to selected mode of impact of treatment components.

3 ex

Novel antibodies // 2490277

FIELD: chemistry.

SUBSTANCE: present invention relates to immunology. Disclosed is an anti-α5β1 antibody, which is described through amino acid sequences of six hypervariable regions and an antigen-binding moiety thereof. Described are conjugates of the disclosed antibodies with a medicinal agent or a label, a pharmaceutical composition, use of the disclosed antibodies to prepare a medicinal agent, methods and an industrial product for inhibiting angiogenesis and/or vascular permeability in a subject, and for treating cancer, an ophthalmic disease and an autoimmune disease in a subject. The invention describes an isolated nucleic acid, an expression vector, a cell and a method of producing an antibody or an antigen-binding moiety thereof, as well as a method of detecting α5β1 protein in a sample.

EFFECT: present invention can find further use in therapy and diagnosis of α5β1-mediated diseases.

52 cl, 11 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of the following general formula [1a], wherein R1 represents (1) a hydrogen atom, (2) C1-C6alkyl group, (3) C2-C6alkenyl group, (4) C2-C6alkynyl group, (5) C1-C6alkoxygroup, (6) hydroxyC1-C6alkyl group, (7) C1-C6alkoxy(C1-C6)alkyl group, (8) -CONR11R12, wherein R11 and R12 are identical or different, and each represents a hydrogen atom or C1-C6alkyl group, (9) phenyl group or (10) a five-member heteroaryl group which contains at least one heteroatom specified in a group consisting of a nitrogen atom and oxygen atom, and which may be substituted by C1-C6alkyl group; R2 represents (1) a halogen atom, (2) C1-C6alkyl group, (3) hydroxy group or (4) C1-C6alkoxy group; p is equal to 0, 1, 2 or 3; X represents a carbon atom or nitrogen atom; m1 is equal to 0, 1 or 2; m2 is equal to 0 or 1; the spiro ring AB may be substituted by 1-5 identical or different, specified in a group consisting of (1) hydroxy group, (2) C1-C6alkyl group, (3) C1-C6alkoxygroup and (4) oxo group; n1 is equal to 0, 1, 2, 3 or 4; n2 is equal to 1, 2, 3 or 4; n3 is equal to 0, 1 or 2, provided n2+n3 is equal to 2, 3 or 4; and a bond presented by the symbol means a single bond or a double bond, provided the three adjoining carbon atoms forms no allene bond presented by formula: C=C=C, or a pharmaceutically acceptable salt thereof.

EFFECT: invention refers to a pharmaceutical composition possessing GPR40 agonist activity, to a GPR40 agonist drugs; to a hypoglycemic agent stimulating insulin secretion on the basis of the above compounds.

45 cl, 42 tbl, 120 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be applied in treatment, prevention and rehabilitation of eye diseases. Realisation of method of eye sclera strengthening includes non-invasive introduction in form of instillation of biological complex based on solution of Altai deer antler extract into conjunctive cavity of eye, in concentration which does not exceed maximal concentration, obtained during extraction of antler components into water or physiological solution. It is possible to additionally realise peroral introduction of microdispersed antler powder.

EFFECT: method ensures fast and effective strengthening of eye sclera.

2 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, namely to localisation facilities for therapeutic sources. The device comprises an applicator implanted into a target area and having at least one guide passage for a radiation source or seed, a number of image-visible support points comprising a number of electromagnetic sensors with the support points being attached to a patient's body and adjoining the target area; what is also provided is an electromagnetic tracking system for localising the electromagnetic sensors on the support points; the device is equipped with a processor to form a brachytherapy session program on the basis of a combination of a relative position of the electromagnetic sensors on the applicator and the electromagnetic sensors on the support points, and images are also presented. According to the second version, the device also comprises a field generator with a number of the electromagnetic sensors for position indication signalling responding to the field generator. One of the electromagnetic sensors is placed on the applicator, and another one - on the target. The device comprises a number of processors for localising the source and target in response to the signals of the electromagnetic sensors.

EFFECT: using the invention enables more accurate planning with reduced radiation load.

14 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, and may be used in hadron radiation therapy of malignant tumours. The method comprises performing the pre-radiation preparation that is patient's body fixation, determination of the malignancy topographometry, development of a conformal irradiation schedule. A conformal irradiation session involves controlling a dose taken by a malignancy, admissible values of the radiation source, radioactivity, temperature of various segments of the radiation source and magneto-optic chains of beam delivery to the malignant tumour. During the pre-radiation preparation and conformal irradiation session, the patient is fixed in an identical adjusted position, the topographometry of the malignant tumours are evaluated, and a hadron beam is delivered to the patient' malignant tumour during an identical respiratory pause in the absence of a cardiac beat pulse wave peak with a constant size of a thorax.

EFFECT: use of the invention allows more precise irradiation of the pancreatic malignancies during respiration not injuring the healthy pancreatic tissues, as well as adjacent tissues and organs.

2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically to oncology and radiology. The method involves the local radiation therapy sessions in a dynamic dose fractionation mode. Additionally, 3 times a week the local radiation therapy session is immediately followed by subtotal irradiation of the upper body from a suprasternal notch to a diaphragm. Thereafter, 21-28 days after the local radiation therapy completed, min. 4 cycles of the chemotherapy with each cycle combined with subtotal irradiation of the upper body from the suprasternal notch to the diaphragm 3 times a week.

EFFECT: method enables reducing a risk of developing a local recurrence of the tumour and metastases to 10,7% as compared to the previously known methods (15%), as well as a severity of complications with achieving the complete objective response to the treatment in 35,7% of the patients, and the partial response - in 46,42%.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology, pulmonology, radiology, radiation therapy of non-small-cell lung cancer. Sessions of the local radiation therapy are daily to a total focal dose equivalent to 60-70 Gy, in a dynamic dose fractionation mode at a single focal dose of 4-2 Gy. Additionally, three times a week immediately after the local radiotherapy session, an upper part of substernal notch to diaphragmare exposed to subtotal irradiation at a single dose of 0.1 Gy to a total dose of 1 Gy.

EFFECT: method provides reducing a risk of local recurrence, distant metastasis, and a severity of acute radiation reactions and injuries, eg pneumonitis, esophagitis, reducing the hematopoietic complications, complete tumour regression in 15,6% of patients with an average life expectancy of 18 months.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology and endocrinology, and can be used for treatment of endocrine ophthalmopathy. For this purpose introduced are: galium heel is introduced in dose 10 drops in 50-100 ml of water 3 times per day, for 3 weeks, reneel in dose 1 tablet sublingually 3 times per day for 3 weeks, injections of cerebrum compositum under skin in dose 2.2 ml 2 times per week, with 3-day interval, 5 injections in total, starting from the first day of treatment, injections of coenzyme compositum under skin in dose 2.2 ml 2 times per week, with 3-day interval, 5 injections in total, as well as hirudotherapy 2-3 leeches on temporal area, starting from the first day of treatment, two times per week, 4-6 procedures in total, with 3-day interval, radiotherapy, starting from the first day of treatment, by means of beta-applicators on projection of thickened muscles with radionuclide Ruthenium-106+ Rhodium 106, 5 sessions, 200 cGy each, daily.

EFFECT: method makes it possible to increase efficiency of treatment of endocrine ophthalmopathy due to reduction of edema of retrobulbar tissue and extraocular muscles with the lowest number of side effects and improvement of parameters of blood of thyroid gland hormones.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology, and radiology, and can find application in a combined method of treating laryngeal and laryngopharyngeal cancers. The method involves applying tracheostoma, approaching and excising the tumor, ensuring wound hemostasis and conducting radiotherapy. The tumour excision is followed by making an intraoperative individual tissue-equivalent applicator formed after the bed of resected larynx or laryngopharynx consisting of a self-polymerising material. Conductive ferromagnetic particles and intrastats of the brachytherapeutic apparatus are pre-inserted into the applicator. The applicator is fixed in the tumour bed; the wound is sutured. The local hyperthermia immediately follows through the applicator at 42-43°C for at least 60 minutes. The brachytherapy is conducted immediately thereafter in a single dose of 10 Gy. On the 7-8th postoperative day, the applicator is removed, and 8-12 days later, the area of the extracted tumor is additionally exposed to the radiation teletherapy (RTT) at a dose of 2 Gy per day, 5 times a week up to a total RTT dose of 24-26 Gy.

EFFECT: method reduces the number of recurrences, provides the radiation dose reduced by 1,5-2 times, reduces the number of complications in healthy tissues.

5 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medical equipment, particularly to X-ray engineering, namely to methods for producing biological objects, specifically blood and its components by the use of ionising radiation. A X-ray apparatus for blood radiation treatment comprises a biologically protected radiation blood chamber, an X-ray generator, an X-ray detector and a control panel for setting an absorbed dose required for radiation. The X-ray generator represents a nanosecond frequency electron accelerator with a semi-conductor circuit breaker and a vacuum diode with a metal-ceramic cathode, and the X-ray detector is designed so that to measure the absorbed dose of pulse X-ray radiation.

EFFECT: use of the invention allows higher dose setup rate combined with relatively low quantum energy.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly oncology, X-ray therapy, chemotherapy and surgery, and may be used in treating locally advanced gastric cancer. That is ensured by pre-operative radiation therapy covering a primary tumour by deceleration radiation, daily for 24 days with weekend rest by daily dose graduation of three-pole exposure as 1 Gy + 1.5 Gy every 4-5 h between the fractions to SRD 45 Gy. The exposure covers a regional metastasis area with the chemotherapy course comprising the preparations eloxatin and capecitabine. The preparation eloxatin is introduced in a dose of 80 to 85 mg/m2 on the 1st and 21st days of the chemoradiation therapy. The preparation capecitabine is introduced in a daily dose of 1670 to 2000 mg/m2 in 2 stages for the entire course of the radiation therapy including weekends. The first introduction of capecitabine is performed 1 hour before the first session of the exposure. Further, 23-29 days later the chemoradiation therapy is followed by a radical surgical intervention including D2 lymphodissection.

EFFECT: method provides an evident therapeutic effect on the primary tumour and regional metastases with good tolerance and a high degree of anti-cancer effect ensured by reduced micrometastases and tumour complexes circulating in blood and lymph.

4 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine. Course of chemotherapy with intravenous drop introduction of 100 mg/m2 of cisplatin, doxorubicin - 30 mg/m2 and vincristine - 4 mg/m2 is carried out. After distant gamma-therapy with bringing onto initial focus and regional lymph nodes of total dose 20 Gy, 11-12 sessions of intracavitary Co therapy by two fractions in 2.5 Gy with 5-hour interval, with rhythm 2 times per week alternating with distant gamma-therapy on regional lymph nodes and weekly intravenous introduction of 250 mg of 5-fluorofuracyl at all stages of irradiation.

EFFECT: application of claimed method makes it possible to increase single and total focus doses in intracavitary irradiation, improve results of combined radiotherapy, reduce reactions to normal tissues of adjacent organs and improve life quality of patients with cancer of said localisation in the process of treatment.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly oncology and surgery, and may be used in treating rectal cancer. That is ensured by teleirradiation, oral administration of capecitabine, intrarectal administration of metronidazole, local SHF hyperthermia followed by a surgical intervention. Capecitabine is administered 2000 mg/m2 from the 1st to 14th days. Metronidazole 10 g/m2 is intrarectally administered on the 3rd and 5th therapeutic days as a part of a composite mixture having the following proportions, wt %: metronidazole 12-22, sodium alginate 4-6, dimethylsulphoxide 2, distilled water up to 100. The 5-hour exposure of metronidazole is followed by a session of teletherapy. The local SHF hyperthermia at temperature 41-45° for one hour follows a session of teletherapy on 3rd, 4th and 5th therapeutic days. The surgical intervention is conducted 4 weeks after the completion of the preoperative therapy.

EFFECT: method provides ensuring complete therapeutic pathomorphism of the tumour in 25% of patients, reducing toxic and post-therapeutic complications, as well as enables conducting sphincter-preserving surgical interventions.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a nanoemulsion as a carrier of a biologically active substance representing a DSIP or a herbal extract. The nanoemulsion contains water, a surfactant representing an ethylene oxide/ propylene oxide block copolymer, and a biopolymer in the form of mixed polysaccharide (PS) and polyaminosaccharide (PAS). The polysaccharide is 2-diethylaminoethyl-dextran or 3-dimethylaminopropyl-dextran. The polyaminosaccharide is chitosan or a chitosan derivative prepared by exhaustive alkylation of primary amino groups by glycidyl trimethylammonium chloride. The mass content of each of the polymers (ethylene oxide/ propylene oxide block copolymer, PS and PAS) in the mixture of polymers and nanoemulsion is found within the range of 0.1 to 0.7, while the ethylene oxide/ propylene oxide block copolymer concentration makes 0.4-4.0 g/l.

EFFECT: invention provides preparing the biologically compatible and storage-stable nanoemulsion.

2 cl, 7 ex

Up!